← Eichor
Condition: Oligodendroglioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Oligodendroglioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Sur
Phase 3 · 26 location(s) · Hospices Civils de Lyon · NCT04702581Implantable Microdevice In Primary Brain Tumors
EARLY_Phase 1 · 1 location(s) · Oliver Jonas · NCT04135807Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase 1/Phase 2 · 1 location(s) · University of Miami · NCT05956821PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
NA · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT06930846All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Phase 2 · 1 location(s) · Stephen Bagley, MD, MSCE · NCT05345002SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Phase 1 · 1 location(s) · University of Nebraska · NCT05698524ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Phase 1 · 1 location(s) · University of Florida · NCT06254326Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendrogl
Phase 2 · 1 location(s) · Henan Provincial People's Hospital · NCT05512351SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Phase 1/Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT04923126FearLess in NeuroOncology
NA · 1 location(s) · Virginia Commonwealth University · NCT06989086Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
Phase N/A · 2 location(s) · LMU Klinikum · NCT07159607Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT01649830Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07462507Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
Phase N/A · 1 location(s) · Xiangya Hospital of Central South University · NCT07608003Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 · 3 location(s) · M.D. Anderson Cancer Center · NCT03911388Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Phase N/A · 3 location(s) · Maastricht Radiation Oncology · NCT04648462A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
Phase 3 · 19 location(s) · University Hospital Heidelberg · NCT05331521Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastom
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04623931
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.